<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239564</url>
  </required_header>
  <id_info>
    <org_study_id>IPX054-B04-06</org_study_id>
    <nct_id>NCT00239564</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease</brief_title>
  <official_title>An Open-Label Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IMPAX Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IMPAX Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to compare the pharmacokinetics and pharmacodynamics of IPX054 and
      carbidopa-levodopa immediate-release tablets in subjects with idiopathic Parkinson's disease
      who are currently being treated with a stable regimen of carbidopa-levodopa immediate-release
      tablets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IPX054 contains two different drugs called levodopa and carbidopa in one tablet.

        -  levodopa turns into a material called 'dopamine' in your brain. The dopamine helps to
           improve the symptoms of your Parkinson's disease.

        -  carbidopa belongs to a group of medicines called 'aromatic amino acid decarboxylase
           inhibitors'. It helps levodopa work more effectively by slowing the speed at which
           levodopa is broken down in your body.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parkinsonian disability at Visits 1 and 5</measure>
    <time_frame>36 Days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Idiopathic Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Experimental: carbidopa and levodopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, or IPX054 300 mg to achieve optimum dosage and dosing frequency as directed by the Investigator for 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX054 100 mg</intervention_name>
    <description>IPX054 containing 25 mg carbidopa and 100 mg levodopa</description>
    <arm_group_label>Experimental: carbidopa and levodopa</arm_group_label>
    <other_name>CD-LD ER 100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX054 150 mg</intervention_name>
    <description>IPX054 containing 37.5 mg carbidopa and 150 mg levodopa</description>
    <arm_group_label>Experimental: carbidopa and levodopa</arm_group_label>
    <other_name>CD-LD ER 150 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX054 200 mg</intervention_name>
    <description>CD-LD CR containing 50 mg carbidopa and 200 mg levodopa</description>
    <arm_group_label>Experimental: carbidopa and levodopa</arm_group_label>
    <other_name>CD-LD ER 200 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX054 250 mg</intervention_name>
    <description>CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa</description>
    <arm_group_label>Experimental: carbidopa and levodopa</arm_group_label>
    <other_name>CD-LD ER 250 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX054 300 mg</intervention_name>
    <description>CD-LD CR containing 75 mg carbidopa and 300 mg levodopa</description>
    <arm_group_label>Experimental: carbidopa and levodopa</arm_group_label>
    <other_name>CD-LD ER 300 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of idiopathic Parkinson's disease

          -  Currently being treated with a stable dosage regimen of immediate-release
             carbidopa-levodopa for at least 3 months.

          -  Must experience at least 3 episodes of &quot;wearing OFF&quot; symptoms and an average of at
             least 2 hours of &quot;OFF&quot; time per day.

        Exclusion Criteria:

          -  Diagnosed with atypical parkinsonism

          -  Prior surgical interventions for Parkinson's disease

          -  Glaucoma

          -  Undiagnosed skin lesion or history of melanoma

          -  Epilepsy or history of seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Impax</last_name>
    <role>Study Director</role>
    <affiliation>Impax Pharmaceuticals, a division of Impax Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Lawrence</city>
        <state>Kansas</state>
        <zip>66045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IPX054</keyword>
  <keyword>Parkinson disease</keyword>
  <keyword>Levodopa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

